Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

A user with PCOS experienced hair loss and found success using a triple dose of O.N.E Omega by Pure Encapsulations after discovering low Omega fatty acids. Biotin provided minimal improvement, but the Omega supplement significantly restored hair.

Clascoterone's European release is expected in Q4 2026, with FDA approval anticipated by mid-2027. The discussion includes questions about the approval timeline and potential acceleration due to unmet needs.

PP405 shows promise for hair regrowth by manipulating stem cell characteristics and lactate dehydrogenase, with Phase 2a trials pending. Google Ventures' $15M investment suggests confidence, but results and market availability remain uncertain.

A 40-year-old shared their positive experience with a second hair transplant at HDC Cyprus, involving 4148 grafts and costing around 9,000 euros. They used oral minoxidil, Dutasteride, biotin, and vitamins to aid recovery and were pleased with the results.

The user is happy with hair regrowth after using finasteride, minoxidil, and microneedling for three months. Others comment on the progress and ask about the routine, lighting, and potential side effects.

Finasteride and Nizoral shampoo with Ketoconazole are used for hair loss treatment. Liquid Chromatography–Mass Spectrometry (LC-MS) is recommended over Enzyme-Linked Immunosorbent Assay (ELISA) for more accurate DHT testing.

A 20-year-old has been using 1mg of dutasteride daily, caffeine shampoo, Nizoral shampoo 2-4 times a week, and pumpkin seed pills for hair growth, noticing regrowth since October. Initial shedding occurred, but improvements are felt, especially at the back of the hair.

A user developed AI software to simulate hair transplants on photos, helping people visualize potential results. The tool offers photo-realistic renderings but advises caution regarding exact outcomes due to various factors.

The conversation is about two new videos on exosomes, focusing on how they work and a Q&A session about their use. Specific treatments for hair loss are not discussed.

The conversation discusses the use of spironolactone, cyproterone acetate, and bicalutamide for hair loss, with concerns about side effects like gynecomastia and depression. Topical spironolactone is considered safe for men and effective when combined with regular treatments.

The conversation is about a user's hair growth progress after 9 months of using oral minoxidil and finasteride, along with dermastamping. The user reports improved hair health and color, with some visible scalp remaining, and no side effects from the treatment.

Clascoterone won't be available in the US until 2028, with EU filings planned for 2027. It's considered an alternative for those who experience side effects from standard treatments like finasteride and dutasteride.

The conversation discusses hair loss treatments, specifically Regenera stem cells and exosomes from 'Cellgenic' umbilical cord donors. The user has been using topical minoxidil 5% and 0.001% estradiol for a year without seeing effects, and another user mentions the importance of microneedling.

A user proposed genetically engineering scalp stem cells to stop androgen receptors from causing hair loss. Others discussed the feasibility, existing research, and potential issues with this approach, including targeting the correct cells and unintended effects.

PP405 is considered a promising potential cure for hair loss, with phase 2 trial results expected in February 2025. Hair cloning is also discussed as a potential ultimate solution, despite significant scientific challenges.

A hair loss regimen involving Dutasteride, Oral Minoxidil, Mesotherapy, Topical Minoxidil/Finasteride, RU58841, Alfatridiol, Microneedling, LLLT, Keto shampoo, Vitamin K/D/Fish oil/Borage Oil/MSM, Oral Castor oil and Niacin. It also mentions products that have been dropped from the regimen due to not being worth the hassle or messing with libido.

HopeMed is upset with Absci for allegedly using misleading information about HMI-115's performance compared to ABS-201. HopeMed plans to take legal action to protect its confidential data and trade secrets.

Kintor Pharma completed patient enrollment for a Phase II trial in China for GT20029, a potential new treatment for hair loss. Some believe GT20029 could replace finasteride if effective, while others discuss finasteride's limited efficacy and potential underreported side effects.

The conversation discusses interest in peptides for hair loss, specifically mentioning ahkCU and ghkCU. A user is considering adding ghkCU to their treatment regimen.

The user shared positive hair regrowth results using Minoxidil 5% and stinging nettle root over six months. They avoided finasteride due to concerns but are open to using it if needed.

Clascoterone 5% solution shows strong potential for hair growth, offering a new treatment for alopecia with minimal side effects. It blocks androgen receptors locally and may be available by late 2026 or early 2027.

The conversation discusses hair loss treatments, including microneedling, Nizoral, LLLT, Minoxidil, and Finasteride. The user experienced initial shedding reduction with Nizoral and LLLT, but shedding resumed with Minoxidil and Finasteride, which is considered a normal part of the treatment process.

User is using a homemade topical treatment with .015% finasteride, 5% minoxidil, and microneedling at .75mm depth. They also use 2% ketoconazole shampoo, various oils, and are considering increasing finasteride concentration due to mixed results.

Human pluripotent stem cells have been used to create hair and skin, potentially offering a new solution for baldness. A user also mentioned starting finasteride but experiencing unexpected hair thinning.

Clascoterone is nearing regulatory submission as a potential new treatment for androgenetic alopecia, with positive Phase III results, while discussions continue about other treatments like PP405, minoxidil, and finasteride. Some users express excitement for clascoterone and Breezula, despite concerns about the effectiveness and practicality of topical treatments.

Hair cloning and new treatments like ET-02, Veradermics (vdphl01), and wound-induced hair neogenesis show promise but are not yet widely available. Current effective treatments include minoxidil, finasteride, and dutasteride, with early intervention being crucial for better outcomes.

Celery juice is discussed as a potential treatment for crown balding, with skepticism from users. The conversation highlights differences between alopecia areata and male pattern baldness.

A new topical treatment called RT1640 claims to reverse AGA using cyclosporine A, Minoxidil, and a new chemical entity, RT175. Users are skeptical due to lack of clinical trial data and inconsistent before-and-after photos.

Shiseido's S-DSC hair regenerative treatment in Japan focuses on improving existing hair by thickening miniaturized follicles, not creating new ones. There is limited patient feedback and long-term data available.

The user is trying a new hair loss regimen including Spirolactone, Finasteride, oral Minoxidil, microneedling, and various supplements. They are experiencing increased shedding and seeking advice on microneedling and treatment effectiveness.